ChehimiJ, CampbellDE, AzzoniLet al.Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol, 2002; 168:4796–4801.
2.
DonaghyH, PozniakA, GazzardBet al.Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood, 2001; 98:2574–2576.
3.
AzzoniL, PapasavvasE, ChehimiJet al.Sustained impairment of IFNgamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: Evidence for a defective reconstitution of innate immunity. J Immunol, 2002; 168:5764–5770.
4.
KnightSC, MacatoniaSE, PattersonS. HIV I infection of dendritic cells. Int Rev Immunol, 1990; 6:163–175.
5.
AzzoniL, ChehimiJ, ZhouLet al.Early and delayed benefits of HIV-1 suppression: Timeline of recovery of innate immunity effector cells. AIDS, 2007; 21:293–305.
6.
AzzoniL, PapasavvasE, MontanerLJ. Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparing. Curr HIV Res, 2003; 1:329–342.
7.
PapasavvasE, OrtizGM, GrossRet al.Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis, 2000; 182:766–775.
8.
ChehimiJ, AzzoniL, FarabaughMet al.Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol, 2007; 179:2642–2650.
9.
DybulM, ChunTW, YoderCet al.Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA, 2001; 98:15161–15166.
10.
DybulM, Nies-KraskeE, DaucherMet al.Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: Effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis, 2003; 188:388–396.
11.
GarciaF, PlanaM, OrtizGMet al.The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS, 2001; 15:F29–40.
12.
OrtizGM, WellonsM, BrancatoJet al.Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA, 2001; 98:13288–13293.
13.
OxeniusA, PriceDA, GunthardHFet al.Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA, 2002; 99:13747–13752.
14.
PapasavvasE, KostmanJR, MounzerKet al.Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med, 2004; 1:e64.
15.
PapasavvasE, PistilliM, ReynoldsGet al.Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS, 2009; 23:369–375.
